Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
About this item
Full title
Author / Creator
Garrelfs, Sander F , Frishberg, Yaacov , Hulton, Sally A , Koren, Michael J , O’Riordan, William D , Cochat, Pierre , Deschênes, Georges , Shasha-Lavsky, Hadas , Saland, Jeffrey M , van’t Hoff, William G , Fuster, Daniel G , Magen, Daniella , Moochhala, Shabbir H , Schalk, Gesa , Simkova, Eva , Groothoff, Jaap W , Sas, David J , Meliambro, Kristin A , Lu, Jiandong , Sweetser, Marianne T , Garg, Pushkal P , Vaishnaw, Akshay K , Gansner, John M , McGregor, Tracy L , Lieske, John C and ILLUMINATE-A Collaborators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Primary hyperoxaluria type 1 is caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. This trial tested whether an oligonucleotide drug can reduce the production of hepatic oxalate.
Alternative Titles
Full title
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Authors, Artists and Contributors
Author / Creator
Frishberg, Yaacov
Hulton, Sally A
Koren, Michael J
O’Riordan, William D
Cochat, Pierre
Deschênes, Georges
Shasha-Lavsky, Hadas
Saland, Jeffrey M
van’t Hoff, William G
Fuster, Daniel G
Magen, Daniella
Moochhala, Shabbir H
Schalk, Gesa
Simkova, Eva
Groothoff, Jaap W
Sas, David J
Meliambro, Kristin A
Lu, Jiandong
Sweetser, Marianne T
Garg, Pushkal P
Vaishnaw, Akshay K
Gansner, John M
McGregor, Tracy L
Lieske, John C
ILLUMINATE-A Collaborators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2507731776
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2507731776
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2021712
